Immunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer

International Journal of Cancer

Volumn 133, Issue 7, 2013, Pages 1743-1750

  Shao, Ning ^a   Wang, Yang ^b   Jiang, Wen Yu ^b   Qiao, Di ^a   Zhang, Shi Ge ^a   Wu, Ye ^a   Zhang, Xiang Xiang ^a   Wang, Jiu Ling ^a   Ding, Yi ^a   Feng, Ning Han ^b  

^a Jiangsu Province Geriatric Hospital   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

CRPC; endothelin receptor antagonists; immunotherapy

Indexed keywords

ATRASENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; IMMUNOMODULATING AGENT; PLACEBO; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; ZIBOTENTAN;

ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CHILL; CONSTIPATION; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG SAFETY; DYSPNEA; FATIGUE; FEVER; HUMAN; NAUSEA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING;

CRPC; ENDOTHELIN RECEPTOR ANTAGONISTS; IMMUNOTHERAPY;

DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY; MALE; ORCHIECTOMY; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; PYRROLIDINES; RECEPTORS, ENDOTHELIN; TISSUE EXTRACTS;

EID: 84880253061     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28162     Document Type: Article

References (42)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Ferlay J, Parkin DM, Steliarova-Foucher E,. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81.
3. Hirst CJ, Cabrera C, Kirby M,. Epidemiology of castration resistant prostate cancer: a longitudinal analysis using a UK primary care database. Cancer Epidemiol 2012; 36: e349-53.
4. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232-7.
5. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-59.
6. Donkena KV, Yuan H, Young CY,. Recent advances in understanding hormonal therapy resistant prostate cancer. Curr Cancer Drug Targets 2010; 10: 402-10.
7. Harris WP, Mostaghel EA, Nelson PS, et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6: 76-85.
8. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
9. Attard G, Sarker D, Reid A, et al. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer 2006; 95: 767-74.
10. Ross RW, Kantoff PW,. Hormone-refractory prostate cancer: choosing the appropriate treatment option. Oncology (Williston Park) 2007; 21: 185-93; discussion 94, 99-200.
11. Warren R, Liu G,. ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. Expert Opin Investig Drugs 2008; 17: 1237-45.
12. Gerritsen WR, Sharma P,. Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J Clin Immunol 2012; 32: 25-35.
13. Tanaka T, Nakatani T,. New therapeutic strategies for castration-resistant prostate cancer. Recent Pat Anticancer Drug Discov 2011; 6: 373-83.
14. Bianchini D, Zivi A, Sandhu S, et al. Horizon scanning for novel therapeutics for the treatment of prostate cancer. Ann Oncol 2010; 21 (Suppl 7): vii43-55.
15. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54.
16. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 4563-71.
17. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-8.
18. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
19. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-46.
20. Jiang J, Liang X, Zhou X, et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2010; 5: 867-73.
21. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 3670-9.
22. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22.
23. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1099-105.
24. Beer TM, Bernstein GT, Corman JM, et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res 2011; 17: 4558-67.
25. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-94.
26. Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008; 113: 2478-87.
27. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110: 1959-66.
28. James ND, Caty A, Payne H, et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU Int 2010; 106: 966-73.
29. Nelson JB, Fizazi K, Miller K, et al. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 2012; 118: 5709-18.
30. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.
31. Galsky MD, Vogelzang NJ,. Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol 2010; 21: 2135-44.
32. Basch EM, Somerfield MR, Beer TM, et al. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-esistant) prostate cancer. J Clin Oncol 2007; 25: 5313-8.
33. Dayyani F, Gallick GE, Logothetis CJ, et al. Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011; 103: 1665-75.
34. Haines AM, Larkin SE, Richardson AP, et al. A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry. Br J Cancer 1989; 60: 887-92.
35. Goldstein NS,. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 2002; 117: 471-7.
36. Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 2004; 60: 197-204.
37. DiPaola RS, Plante M, Kaufman H, et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med 2006; 4: 1.
38. Arlen PM, Skarupa L, Pazdur M, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 2007; 178: 1515-20.
39. Nelson JB, Chan-Tack K, Hedican SP, et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996; 56: 663-8.
40. Wu-Wong JR, Chiou WJ, Dickinson R, et al. Endothelin attenuates apoptosis in human smooth muscle cells. Biochem J 1997; 328 (Part 3): 733-7.
41. Rosano L, Di Castro V, Spinella F, et al. ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation. Exp Biol Med (Maywood) 2006; 231: 1132-5.
42. Growcott JW,. Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054. Anticancer Drugs 2009; 20: 83-8.